Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.
Two biosimilars for the TNF inhibitor infliximab are now licensed and distributed in Europe. A German rheumatologist wonders what difference the option to prescribe Inflektra and Remsima will make, if any.
Do you think heavy lifting with degenerative osteoarthritis is the major cause of low back pain? A new study designed to identify modifiable triggers finds relative youth, time of day, and perhaps lack of planning to be key factors.
Registry data show that smokers with spondyloarthropathies have markedly less improvement in disease activity on TNF inhibitors. The evidence also suggests that quitting the smoking habit erases this disadvantage.
Antinuclear antibody testing and DEXA both appear on a new Canadian list of rheumatology tests to avoid and on a similar 2013 list from the American College of Rheumatology. There are interesting differences in the other 3 choices.
Patients with spondyloarthropathy may have increased risks for adverse events when starting NSAIDs for the first time, a registry study suggests. But doctors' caution in using these drugs among patients with comorbidities made the analysis complex.